In pharmaceutical development the term “evergreening” is a lightning rod. To its critics—consumer advocates, public health officials, and generic drug […]

The economic reality of contemporary drug discovery suggests that the traditional model of pharmaceutical research is becoming an exercise in

In pharmaceuticals market exclusivity is the ultimate prize. It is the golden period during which an innovator company can recoup

The Capital Efficiency of Repurposed Innovation Pharmaceutical companies face a brutal economic reality. Developing a new chemical entity now requires

The pharmaceutical industry operates on a punishing mathematical reality. In 2024, generic and biosimilar medicines accounted for 90% of all

Money is moving. The global pharmaceutical industry is currently witnessing a structural relocation of profit that will redefine the balance

The Pricing Shock: How the Inflation Reduction Act Rewrites the Valuation Rules The economic foundations of the pharmaceutical industry are

Direct-to-consumer (DTC) pharmaceutical companies are no longer just apps for convenience. Hims & Hers and Ro have spent the last

The economics of the leaky bucket In the pharmaceutical business, time is the only currency that truly matters. Inventors often